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Intranasal infection with vaccine strain of Venezuelan equine encephalitis virus
(TC83) caused persistent viral infection in the brains of mice without functional αβ
T-cells (αβ-TCR −/−). Remarkably, viral kinetics, host response gene transcripts and
symptomatic disease are similar between αβ-TCR −/− and wild-type C57BL/6 (WT)
mice during acute phase of infection [0–13 days post-infection (dpi)]. While WT mice
clear infectious virus in the brain by 13 dpi, αβ-TCR −/− maintain infectious virus in the
brain to 92 dpi. Persistent brain infection in αβ-TCR −/− correlated with inflammatory
infiltrates and elevated cytokine protein levels in the brain at later time points. Persistent
brain infection of αβ-TCR−/−mice provides a novel model to study prolonged alphaviral
infection as well as the effects and biomarkers of long-term viral inflammation in the
brain.
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INTRODUCTION
Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne arbovirus of the family
Togaviridae. Evidence for re-emergence of VEEV infections have been identified, although large
outbreaks have not been recently observed (Weaver et al., 1996; Rivas et al., 1997). VEEV has a
large region where the mosquito vector can be found, setting it as an important emerging infectious
disease (Taylor and Paessler, 2013). This is supported by the fact that VEEV is more commonly
found in Central and South America than in the United States (Morrison et al., 2008). VEEV’s
presence in low-income regions provides the opportunity to develop strategies and improved
quality of life to individuals in low-income countries suffering from severe health disparities, as
the hours lost to work in these countries severely affect the health and well-being of the entire
family structure (Kankeu et al., 2013).
Humans infected with VEEV develop a febrile illness averaging 1–5 days after exposure that can
be followed by encephalitis, but asymptomatic infections do occur. The average case fatality rate of
VEEV is 1%, but 15% of survivors can be left with severe neurological complications. Currently,
there are no licensed vaccines in the United States for use in humans. However, live-attenuated
vaccines have been used in the US military and laboratory workers and formalin-inactivated
vaccines are available for use in horses.
One such live-attenuated vaccine is TC-83, originally developed by the US Army for vaccine use
(Pittman et al., 1996). TC-83 was created by serially passaging the Trinidad Donkey VEEV strain
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in guinea pig heart cells (Alevizatos et al., 1967). Point mutations
in E2 and the 5′ untranslated region are responsible for the
attenuated phenotype of TC-83 (Kinney et al., 1993). TC-83
has been noted to be effective in preventing disease in humans,
but 15–37.5% of vaccine recipients develop febrile symptoms
(Berge et al., 1961; McKinney et al., 1963; Alevizatos et al., 1967;
Pittman et al., 1996) and only 82% of vaccinees seroconvert upon
vaccination. The probability of plaque reduction neutralization
titer remaining ≥1:20 over a period of 5–8 years was 60%. Since
TC-83 is only available for use as an investigational vaccine
and the population to which it is available is limited, additional
studies to evaluate the immunogenicity of the vaccine in humans
over time are not available. Of interest to this study is that
following intranasal infection with the vaccine strain of VEEV-
TC-83, C57BL/6 (WT) mice develop disseminated infection of
the brain with high infectious titers without mortality (Hart
et al., 1997; Steele et al., 1998; Julander et al., 2008; Taylor et al.,
2012).
T cells are an important aspect to the adaptive immune
response and control of viral infections. Previously, CD4+
T-cells were demonstrated as crucial in resolution of VEEV-
viral brain infection in murine models (Paessler et al., 2007;
Yun et al., 2009). Using this knowledge, we tested the
hypothesis that T-cells contributed to survival of WT mice
following high-level viral replication (TC83 strain) in the
brain by evaluating the persistence of virus and the associated
cytokine expression between WT and T cell receptor knockout
mice.
MATERIALS AND METHODS
Mice and Virus Challenge
Four to 8-week-old female mice with ablated CD4+ and CD8+
T-cell responses due to disruption in T-cell receptor β chain
(αβ-TCR −/−) were purchased from Jackson Laboratories (CN#
002118). Four to 8-week-old female wild-type (WT) C57BL6/J
mice were purchased from Jackson Laboratories (CN# 000664).
All studies were carried out in the ABSL-2 or ABSL-3 as required
and were approved by the Institutional Animal Care and Use
Committee at the University of Texas Medical Branch. Animals
were intranasally infected with 107−8 plaque forming units of
TC-83 in 40 µL of saline or saline alone.
Viral Replication
Organs were homogenized and viral load in the organs was
determined by plaque assay on Vero cell monolayers as
previously described (Taylor et al., 2012). Statistical analysis
and comparison was performed using a two-tailed unpaired
student’s t-test with 95% confidence interval in GraphPad R© Prism
(San Diego, CA, USA). In the event the F test to compare variance
was significantly different, student’s t-test was used with Welch’s
correction.
Neutralizing antibody was measured by plaque reduction
neutralization test as previously described, and geometric mean
titers are reported as the reciprocal of the serum dilution
corresponding to an endpoint of 50% plaque reduction. For
PRNT values below the limit of detection (<20), an arbitrary
value of 1 was used for calculation (Taylor et al., 2012).
Histopathology
Histology of the brain was performed by a blinded
neuropathologist as previously described (Taylor et al., 2012).
In brief, sections were scored semi-quantitatively using a 0–3
scale. On this scale, 0 represents no inflammation or necrosis,
1 represent mild-minimal inflammation, 2 represents moderate
inflammation, and 3 represents moderate/severe inflammation
(Taylor et al., 2012).
Cytokine Analyses
Brain homogenates were utilized to determine cytokine levels.
IFN- β levels were determined by ELISA, as per manufacturer’s
instructions. Brain homogenate levels of 23 cytokines and
chemokines were determined using Bio-Plex Pro Mouse
Cytokine 23-plex Assay (Bio-Rad #M60-009RDPD) as per
manufacturer’s instructions. Replicates of three mice per group
per time point were used. Statistical analysis was performed as
described for viral load.
Microarray Analysis
Total brain RNA preparation, GeneChip processing and
microarray analysis were performed as previously described
(Taylor et al., 2012). The microarray data from this study
can be accessed at http:// www.ncbi.nlm.nih.gov/geo/, accession
number GSE91074. Transcripts with low probability values
adjusted for multiple testing (p < 0.0001) and log2 (fold
change)> 1 were qualified as differentially expressed.
RESULTS
Both Strains of Mice Develop Acute
Symptomatic Disease Following TC-83
Intranasal Infection
In WT and αβ-TCR −/− mice, infectious virus was initially
detected in the brain at 1 dpi (n = 3/group), and peak viral
loads in the brain occurred at 6 dpi with 100% of tested
samples positive. At 6 dpi, the viral burden in the brain of
WT mice (4.2 × 106 ± 1.7 × 106 pfu/g) was lower than
αβ-TCR-/- mice (1.2 × 109 ± 1.9 × 109 pfu/g) (Figure 1).
No infectious virus was found in the brains of WT mice
past 8 dpi (Figure 1). Reduction in brain viral load was
observed preposition? αβ-TCR −/− mice between 6 and 13 dpi
dropping from a peak of 1.2 × 109 ± 1.9 × 109 pfu/g to
1× 105 ± 1.1× 105 pfu/g.
In the peripheral organs, low level of infectious virus
(<103 pfu/g) presented in the lung and spleen at 6 dpi only.
Infectious virus was detected in the lung in 33% of WT and
αβ-TCR −/ − mice, and in the spleen in 66% of WT mice
only, and no virus was found in the liver in either strain
(n= 3/group).
Acute symptomatic disease developed following TC-83
infection in both strains of mice. Symptomatic clinical disease
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FIGURE 1 | Mice without functional CD4 and CD8 T-cells (αβ-TCR −/−) and immunocompetent wild-type mice (WT) develop a similar acute phase
(D0–D13) viral kinetic and disease response to TC83 infection. Viral load in the brain as determined by plaque assay at 1, 5, and 13 dpi. αβ-TCR −/− and WT
mice display similar viral kinetics over time with viral load peaking at 6 dpi. Combined results of two independent experiments at 6 dpi. n = 3 at 1 dpi, n = 10 at 6 dpi
n = 6 at 13 dpi for αβ-TCR −/−; n = 3 at 1, 6, and 13 dpi for WT. Mock treated controls (n = 3/time point) displayed no virus at any time point. Significance
determined by student’s t-test p < 0.01. Symptomatic disease as measured by weight loss relative to mock controls. αβ-TCR −/− and WT mice display similar
weight loss patterns early in disease. n = 15 at −5, 0 dpi; n = 12 at 2, 5 dpi; n = 9 at 9, 12, and 15 dpi. Significance determined by 2-way ANOVA with Sidak’s
multiple.
was characterized by weight loss. Other clinical signs were rarely
observed and limited to piloerection and hunching. Peak weight
loss correlated with peak disease in both WT and αβ-TCR −/−
mice (Figure 1). However, infected WT maintained significantly
greater weight loss than mock controls at 15 dpi (Figure 1).
The Acute Host Response in the Brain Is
Similar between αβ-TCR −/− and WT
Mice at Peak of Infection and Disease
Both αβ-TCR −/− and WT mice developed neutralizing
antibody with all serum samples testing positive at 12 dpi (n = 8
αβ-TCR−/−, n= 9 WT). However, titers were lower in αβ-TCR
−/− mice with a range from 40 to 160 with a geometric mean
titer of 93 compared to WT with a range from 640 to 2560 with
geometric mean titer of 1351 in WT. Interestingly, in αβ-TCR
−/−mice reduction of viral load at 13 dpi occurred in the absence
of both functional αβ T-cells and significant levels of neutralizing
antibody. This indicates that control of infection and disease may
be partially attributed to other immune effectors.
In addition to host antibody responses, we contrasted
the transcriptional responses of TC83-infected relative mock-
infected αβ-TCR −/− and WT mice at the peak of acute disease
associated with uniform high viral load in the brain and clinical
symptoms, 6 days post-infection. No transcripts simultaneously
possess low probability values and high fold change, so none were
qualified as differentially expressed. Transcriptome analysis early
in infection (at 6 dpi) identified undistinguishable response to
intranasal TC-83 inoculation in brains of either WT or αβ TCR
−/−mice.
To further clarify the host responses in the brain between
αβ-TCR −/− and WT mice, we analyzed 23 cytokine levels in
brain homogenates at 1 and 6 dpi.
Virus Persisted in the Brains of
αβ-TCR −/− to 92 dpi
Viral load in the brains of αβ-TCR −/− mice was maintained
over time following initial reduction after 6 dpi (Figure 1). On
33–34 dpi 60% of tested brain homogenates were positive for
infectious virus with brain viral load ranging from undetectable
to greater than 105 pfu/g (Figure 2A). Only one sample
was positive at 61 dpi, but, at 92 dpi, all tested brain
samples demonstrated the presence of infectious virus in the
brain.
αβ-TCR −/− infected mice returned to a weight similar to
mock controls after 19 dpi (Figure 2B). Interestingly, WT mice
failed to regain lost weight continued to lose weight to 47 and
maintained a weight significantly lower than mock controls to
end of study (Figure 2B).
A Chronic Pro-inflammatory Cytokine
Response in the Brain Characterizes
Persistently Infected αβ-TCR −/−
A chronic pro-inflammatory cytokine response was observed in
αβ-TCR −/− mice. At 34 dpi signs, mononuclear cell infiltrates
and meningitis are still apparent αβ-TCR−/−mice (Figure 2C).
Additionally, neutrophilic infiltrates associated with neuronal
necrosis are apparent in the brain tissue at 34 dpi. RANTES and
MCP1 are significantly higher in the brains of TC83 infected
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FIGURE 2 | αβ-TCR −/− mice develop persistent (D13+) viral infection of the brain associated with continued inflammation. (A) Viral load in the brain as
determined by plaque assay. αβ-TCR −/− mice maintain infectious virus in the brain to 92 dpi. Combined results of two independent experiments at 33–34 dpi.
n = 9 at 33–34 dpi; n = 3 at 61, 92 dpi (B) Symptomatic disease as measured by weight loss relative to mock controls. By 19 dpi, αβ-TCR −/− display similar
weight to mock mice; in contrast, WT mice fail to return to mock treated weight levels at later time points. n = 9 at 19, 25 dpi; n = 6 at 34, 47, and 61 dpi; n = 3 at
92 dpi. (C) Characteristic signs of inflammation in persistently infected αβ-TCR −/− mice at 30 dpi including activated microglia, perivascular cuffing, and increased
cellular infiltrates. Significance determined by 2-way ANOVA with Sidak’s multiple comparison.
mice compared to mock αβ-TCR −/−mice at 34, 61, and 92 dpi
(Figure 3). IFN-β levels also were elevated in persistently infected
αβ-TCR −/− mice compared to controls at 6, 13, and 34 dpi.
The continued elevation of RANTES and MCP-1 between 34 and
92 dpi in αβ-TCR −/− mice indicates the ongoing infectious
processes in the brain, and these cytokines are consistent with the
production of antiviral type I interferons.
In contrast to αβ-TCR −/− mice, the cytokine levels in WT
mice steadily drop from 34 to 61 dpi returning to baseline by
92 dpi (Figure 3).
Frontiers in Microbiology | www.frontiersin.org 4 January 2017 | Volume 8 | Article 81
fmicb-08-00081 January 24, 2017 Time: 14:52 # 5
Taylor et al. TC83 Persistent Brain Infection
FIGURE 3 | αβ-TCR −/− mice develop a unique pro-inflammatory cytokine signature that characterizes ongoing inflammation. Cytokine levels in brain
homogenate as determined by multiplex cytokine array at 34, 61, and 92 dpi in αβ-TCR −/− and WT mice. αβ-TCR −/− display increased cytokine levels to 92 dpi.
Significance determined by 2-way ANOVA with Sidak’s multiple comparisons. n = 3 per group.
DISCUSSION
The novel finding of viral persistence in the brains of αβ-TCR
−/− mice combined with indicators of chronic inflammation
and/or potential virus persistence below the limit of detection in
WT mice requires further study. T-cells appear to be crucial to
complete viral clearance and disease resolution in TC83 infection.
In absence of functional T-cells and poor neutralizing antibody
response, TC83 infection produces higher virus titers in the brain
than in brains of wild-type mice. However, higher, chronic brain
viral load does not translate to lethal disease indicating that other
immune factors apart from antibody or T-cells are responsible for
resistance to viral neurological diseases.
The ongoing weight loss in WT mice possibly indicates
ongoing pathogenesis with a viral burden below the limit of
detection or illness associated with regenerative process in
the brain. Although virus was not detectable by plaque assay,
this weight loss coincided with ongoing expression of pro
inflammatory cytokines in WT mice. The slow decline in cytokine
levels could be explained by either regenerative process in the
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brain after TC83-encephalitis, or continuous presence of virus
below the limit of detection.
Chronic infection following alphaviral encephalitis has been
reported in the literature in different models (Steele et al., 1998;
Hart et al., 2000; Paessler et al., 2007; Brooke et al., 2010). In
combination with our model of chronic infection in αβ-TCR
−/−mice, data indicates that T-cells are crucial to complete viral
clearance and resolution of infection. However, other immune
factors may be key in preventing mortality and in allowing the
long term asymptomatic, persistence of virus in the brain. We
believe that this novel model will be very useful in examining
both the process of chronic viral brain infection and the host
response to persistent brain infections. It is also noteworthy that
the human vaccine TC83 can persist in the brain of αβ-TCR
−/− mice without detectable clinical disease, which raises safety
concerns regarding the use of the vaccine in human populations
and warrant further investigations.
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